Innate Pharma

Report Publication Announcement • Apr 17, 2009

INNATE PHARMA UPDATES ON ITS NEXT MEETINGS WITH ANALYSTS AND INVESTORS

Marseilles, France, April 17, 2009

Innate Pharma (Euronext Paris: FR0010331421 – IPH), a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases, announces it will participate to the following analyst and investor conferences in the coming weeks:

• BioCapital Europe, April 21, 2009, in Amsterdam, The Netherlands;
• C,F&B Smallcap Event, April 27-28, 2009, in Paris, France;
• BioEquity Europe, June 9-10, 2009, in Munich, Germany.

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website (www.innatepharma.com) and contact the investor relations team by writing to investors@innatepharma.com.

About Innate Pharma

Innate Pharma S.A. (the "Company") is a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. Founded in 1999, it was initially listed on NYSE-Euronext in Paris in 2006.

The Company has a significant expertise in bringing novel targets to the clinical proof-ofconcept trials of drug candidates. It currently has seven proprietary drug-candidates (two of which in clinical trials) and two programs out-licensed to Novo Nordisk A/S.

Based in Marseilles, France, Innate Pharma had 89 employees as at December 31, 2008.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information

ISIN code FR0010331421 Ticker code IPH

Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Innate Pharma to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For any additional information, please contact:

Innate Pharma	Alize Public Relations
Laure-Hélène Mercier,	Caroline Carmagnol
Director, Investor Relations	Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87	Mob: +33 (0)6 64 18 99 59
lmercier@innate-pharma.fr	caroline@alizerp.com